<qa>  What is the goal of the study?Thus, we are proposing an efficacy study of anti-PD1 treatment after transplant to improve MM treatment outcomes. This is a collaborative study with Medical College of Wisconsin headquarter of Center for International blood and Marrow Transplant Research. We hypothesized that anti-PD1 treatment will increase the MM response and the MM control duration when it is added to the standard MM treatment after transplant. Anti-PD1 will be given at the dose and interval, which had been studied previously 200 mg intravenous injection every 3 weeks between 2 weeks until 6 months after transplant. Subjects will be monitored closely during and after anti-PD1 therapy until at least 1 year post transplant. Late complications will be followed until 3 years. 